Maravai LifeSciences to Acquire Officinae Bio's DNA and RNA Business

Maravai LifeSciences Acquires MyChem

January 28, 2022

Biotechnology

Maravai LifeSciences (NASDAQ: MRVI) acquired MyChem, LLC, a San Diego-based provider of ultra-pure nucleotides, for $240 million in cash plus potential contingent consideration. The acquisition integrates MyChem into Maravai's TriLink nucleic acid production business to expand capabilities for mRNA synthesis, accelerate R&D and support GMP manufacturing for vaccine, therapeutic and diagnostic customers.

INVO Bioscience Acquires NAYA Biosciences in All-Stock Merger

October 14, 2024

Healthcare Services

INVO Bioscience and NAYA Biosciences entered into a definitive all-stock merger agreement under which INVO would acquire 100% of NAYA in a reverse triangular merger. The combined company operates as NAYA Biosciences and trades on NASDAQ under the “NAYA” ticker after closing.

Acuitas Therapeutics Acquires Majority Stake in RNA Technologies & Therapeutics

January 9, 2026

Biotechnology

Acuitas Therapeutics has acquired a majority stake in RNA Technologies & Therapeutics (RNA T&T), deepening a long-standing collaboration to integrate RNA payload design and LNP delivery capabilities. The investment will support RNA T&T's growth—expanding its algorithmic RNA-sequence optimization platform and small-batch GMP production—while both companies continue to operate independently and offer streamlined capabilities to partners.

Asahi Kasei Medical to Acquire Bionova Scientific

April 14, 2022

Healthcare Services

Asahi Kasei Medical, through a U.S. subsidiary, has agreed to wholly acquire Bionova Scientific, LLC, a U.S.-based biopharmaceutical CDMO providing contract process development and GMP-compliant contract manufacturing services. The acquisition will add CDMO capabilities to Asahi Kasei Medical’s existing bioprocess business and broaden know-how-driven services for next-generation antibody drugs.

Moderna Acquires OriCiro Genomics K.K. for $85 Million

January 5, 2023

Biotechnology

Moderna has entered into a definitive agreement to acquire OriCiro Genomics K.K. for $85 million. The deal is intended to add cell-free DNA synthesis and amplification technologies that complement Moderna’s mRNA manufacturing expertise and accelerate its R&D.

Biotage AB Acquires ATDBio

October 20, 2021

Biotechnology

Swedish life sciences company Biotage AB has acquired UK-based oligonucleotide specialist ATDBio for approximately £45 million in cash and shares. The deal brings ATDBio’s complex DNA/RNA synthesis capabilities and its founders into the Biotage Group to accelerate capability expansion and scale molecular diagnostics, therapeutics and sequencing support services.